OR Royalties

Showing 5000 articles
Business

OR Royalties: A Buying Opportunity After Pullback, or a Sign of Overheating?

Shares of OR Royalties (TSX:OR) have retreated nearly 15% over the past week, prompting investors to reassess the valuation of the precious metals royalty company following its multi-year bull run. With the stock still up significantly year-over-year, we examine whether the dip presents a value entry or reflects justified concerns over its premium pricing.

Business

Idorsia's Latin American Gambit: QUVIVIQ Deal with EMS Signals Strategic Shift Amid Pipeline Scrutiny

Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.